Journal of Metabolic Syndrome

Surekha Rani Hanumanth

Publications

• Review Article
  Metformin Combinatorial Therapy for Type 2 Diabetes Mellitus
  Author(s): Keerthi Kupsal, Saraswati Mudigonda, Nyayapathi VBK Sai, Krishnaveni Neelala and Surekha Rani HanumanthKeerthi Kupsal, Saraswati Mudigonda, Nyayapathi VBK Sai, Krishnaveni Neelala and Surekha Rani Hanumanth
  
  Type 2 Diabetes mellitus (T2D) is a worldwide chronic epidemic with increasing incidence. The current algorithm for medical management of type 2 diabetes includes the pharmacological treatment with nine classes of anti-diabetic drugs. Among the nine classes of drugs approved, metformin, an oral hypoglycemic agent from the biguanide family is widely prescribed as the first-line anti-diabetic monotherapy for the treatment of initially diagnosed T2D individuals. The failure of monotherapy to achieve sustain glycemic control prompted the early use of aggressive combination therapies with other anti-diabetic drugs. The primary aim of T2D treatment is to achieve target glycemic control and reducing further complications of diabetes. Hence, fixed dose combination drugs are preferable in order to reduce pill burden and capital investment. Single pill combinations containing drugs for two diff.. Read More»
  DOI: 10.4172/2167-0943.1000210

  Abstract PDF